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Keywords: Meningococcal disease; Treatment; ChildrenA B S T R A C TMeningococcal disease is a life-threatening infection that may progress rapidly, even after appropriate
treatment has commenced. Early suspicion of the diagnosis is vital so that parenteral antibiotic treatment
can be administered as soon as possible to reduce the complications of infection. The outcome of
meningococcal disease is critically dependent on prompt recognition of two important complications: shock
and raised intracranial pressure. Rapid recognition of disease and of these complications, together with
appropriate management is crucial to the outcome of affected patients. This article summarizes the clinical
features of invasive meningococcal disease, diagnostic tools, treatment modalities, and common
post-infection sequelae.
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http://dx.doi.org/10.1016/j.jadohealth.2016.04.013Infection with the bacterial pathogen Neisseria meningitidis is
the predominant cause of meningitis and septicemia globally
[1,2]. Humans are the only reservoir for the bacterium, which
resides primarily in the nasopharynx; colonization occurs in
approximately 10% of adults and can increase to 24% during
adolescence [3e5].
Prompt recognition of meningococcal infection and aggres-
sive early treatment are of paramount importance in reducing
mortality, which occurs in approximately 10% of those with
invasive meningococcal disease (IMD), even with treatment, and
can reach as high as 50% in those left untreated [6].
The rapid recognition of IMD is of critical importance to
patient survival and outcomes. Understanding the signs of
infection is particularly important in industrialized countries,
such as the United States and United Kingdom, where disease
rates are low and physicians will likely see few cases over the
course of their practice. Prompt administration of effectiveparenteral antimicrobial therapy and early recognition and
management of the complications of IMD, including shock and
raised intracranial pressure (ICP), are critical to improving
patient outcomes. This manuscript will review the clinical fea-
tures of IMD, methodologies for identiﬁcation of the bacterium,
current treatment modalities, and post-infection sequelae.Clinical Features of Invasive Meningococcal Disease
The initial onset of IMD follows the clinical course of a classic
bacterial infection which may pose a challenge for the attending
physician. Typically, a nonspeciﬁc febrile illness with chills,
muscle aches, nausea, and vomiting may precede the develop-
ment of more speciﬁc features of meningococcal infection, such
as classic features of meningitis (e.g., headache, neck stiffness,
photophobia, and altered mental state); however, less than a
third of patients will present with this traditional “typical”
diagnostic combination [5,7]. In approximately 40%e70% of
patients with meningococcal disease, the nonspeciﬁc features
will progress to sepsis due to meningococcal septicemia, with
signs of circulatory insufﬁciency, shock, and the pathognomonic
petechial/purpuric rash [8].
Meningitis and septicemia are the most common clinical
features of IMD and each can occur independently or in
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rash is pathognomonic of IMD and reﬂects coagulopathy. Coa-
gulopathy is universal in severe sepsis regardless of the etiology,
but the pathognomonic hemorrhagic rash is a distinguishing
feature of IMD. The petechiae and purpura may occur anywhere
on the body, so their presence with fever and signs of sepsis
should automatically suggest IMD and prompt the initiation of
immediate parenteral antimicrobial therapy. It should be noted
that the classic rash may not be present until the disease is well
advanced and may be atypical or absent in a signiﬁcant propor-
tion of IMD cases [9].
Shock is a consistent feature of meningococcal septicemia and
is multifactorial in origin due to the consequence of several
pathophysiologic processes, including endothelial cell dysfunc-
tion, myocardial dysfunction, altered vasomotor tone, and
impaired cellular metabolism [10]. Shock occurs because perfu-
sion of vital organs, such as the brain and heart, is maintained at
the expense of perfusion of less vital organs (e.g., skin, kidneys,
and gut). In the early phase of shock, vasoconstriction reduces
blood ﬂow to skin, peripheries, and certain organs, particularly
the kidneys and gut, and patients usually present with cool
peripheries, prolonged capillary reﬁll time, and oliguria. It should
be noted that children may have normal blood pressure until
shock is advanced. In severe cases, focal ischemia of the skin or
even whole limbs may occur as well as renal failure. Despite the
presence of shock, brain perfusion and function is often relatively
well preserved until the disease is far advanced, which can lead
to an underestimation of the degree of cardiovascular collapse by
less-experienced clinicians. Eventually, a decreased level of
consciousness indicates loss of cerebral vascular autoregulation
and reduced brain perfusion.
Septic shock can lead to and is the consequence of impaired
myocardial function, the origin of which is multifactorial:
hypovolemia leads to decreased cardiac ﬁlling; metabolic
derangements (including hypoxia, acidosis, hypokalemia, hypo-
calcemia, hypophosphatemia, hypomagnesemia, and hypogly-
cemia) lead to impaired myocardial contractility. In addition,
bacterial products and inﬂammatory cytokines directly suppress
myocardial contractility. Plasma interleukin-6 has been identi-
ﬁed as a speciﬁc myocardial depressant factor in meningococcal
septicemia [11]. Myocardial contractility may improve with
volume resuscitation and correction of metabolic derangements,
but patients with signs of ongoing shock despite adequate
volume resuscitation require inotropic support to improve
myocardial function.
The onset of hypotension signiﬁes a failure of homeostatic
mechanisms. It should be remembered that diagnosis of shock in
children does not rely on the presence of systemic hypotension.
Children may have normal blood pressure until shock is
advanced.
Raised ICP occurs as a result of inﬂammation of the
meninges and capillary leak in the brain, leading to cerebral
edema. Most patients with meningococcal meningitis have
mildly raised ICP, but signiﬁcantly raised ICP is uncommon.
Although most critically ill children with meningococcal
infection have shock as their primary clinical problem, some
present with meningitis and raised ICP as their predominant
clinical manifestation. Signs of raised ICP include declining
level of consciousness, focal neurologic signs (including
unequal, dilated, or poorly responsive pupils; relative hyper-
tension; and bradycardia), and papilledema (a late ﬁnding in
acutely raised ICP).Identiﬁcation of Meningitis: Lumbar Puncture and
Computed Tomographic Imaging
Lumbar puncture (LP) is a deﬁnitive diagnostic tool that can
yield rapid microbiological conﬁrmation of meningococcal
meningitis and can exclude other causes of meningeal infection.
In the absence of antibiotic treatment before assessment, LP
detects meningococcus in 90% of meningitis-positive patients
while blood cultures detect 40%e75% of cases [12]. It should be
noted that antibiotic treatment before LP reduces the efﬁcacy of
bacterial detection by multiple methods (e.g., cerebrospinal ﬂuid
culture, polymerase chain reaction, latex agglutination) [13].
Although microbiological conﬁrmation is important for estab-
lishing disease etiology, LP may be dangerous in the presence of
raised ICP or shock because it may cause cerebral herniation or
further cardiovascular compromise; consequently, this
procedure should be avoided in the initial assessment of patients
with clinically apparent meningococcal disease. Contraindica-
tions to LP include cardiorespiratory insufﬁciency, raised ICP
(evidence for which includes ﬂuctuating or deteriorating levels
of consciousness [Glasgow Coma Score  8]; normal or high
blood pressure in the presence of a slow or normal heart rate;
unequal, dilated, or poorly reacting pupils; focal neurologic signs
or abnormal posturing; seizures; and papilledema) and coagul-
opathy [14]. When LP is contraindicated, blood culture,
polymerase chain reaction, urine antigen detection, skin biopsy,
and serum inﬂammatory markers can be used to establish a
diagnosis [13].
Computed tomographic brain imaging is frequently used in
patients with a depressed level of consciousness and is particu-
larly recommended where there is a broader differential
diagnosis. However, cranial computed tomographic scanning is
not a sensitive way of assessing ICP and cannot help in making
the decision to perform an LP, which must be made on the basis
of clinical assessment [14].
Treatment of Invasive Meningococcal Disease
Treatment guidelines have been developed over many years.
These are regularly updated and are useful reminders of the
management principles for infants, children, and young adults
with meningococcal septicemia and meningitis, leading to
substantial improvements in mortality (Figures 1e3). Recogni-
tion andmanagement of shock and/or raised ICP is the priority in
effective treatment of IMD. Early and aggressive ﬂuid resuscita-
tion is associated with improved survival in pediatric septic
shock [15]. In the absence of shock, ICP can be treated with
osmotherapy to reduce cerebral edema and improve brain
perfusion.
In the newly diagnosed patient, parenteral antimicrobial
therapy is a top priority and should be given as quickly as
possible and certainly within 1 hour of recognition of IMD as
recommended in the most recent national and international
guidelines (Table 1) [14,16]. It should be noted that patients
with IMD can transmit meningococci within the ﬁrst 24 hours
of antibiotic therapy, therefore, measures such as droplet pre-
cautions should be taken to minimize exposure to health care
workers [17]. Antibiotic therapy rapidly reduces circulating
plasma endotoxin levels in patients with IMD; increased
endotoxin levels have been associated with severity of illness,
including the presence of septic shock, multiple organ failure,
and death in patients with IMD [18]. Even with antibiotic
Figure 1. Management of meningococcal disease in children and young people. Eighth edition, incorporates NICE Bacterial Meningitis and Meningococcal Septicaemia
Guideline CG102. Distributed in partnership with NICE. A&E ¼ accident and emergency; ABC ¼ airway, breathing, circulation; CT ¼ computed tomography; CXR ¼ chest
x-ray; D/W ¼ discuss with; ECG ¼ electrocardiogram; ET ¼ endotracheal; FFP ¼ fresh frozen plasma; GCS ¼ Glasgow Coma Scale; ICP ¼ intracranial pressure; IO ¼
intraosseous; IV ¼ intravenous; LP ¼ lumbar puncture; NICE ¼ National Institute for Health and Care Excellence; NG ¼ nasogastric; od ¼ once daily; PEEP ¼ positive
end expiratory pressure; PICU ¼ pediatric intensive care unit; PR ¼ per rectum; qds ¼ 4 times daily.
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considerably lower than the 70%e85% mortality rate observed
before the availability of antibiotics [19].
Cefotaxime, ceftriaxone, and penicillin are preferred as initial
therapy in patients with a clinical diagnosis of IMD [17]. In a
retrospective review of hospital records that included 381
patients with IMD, mortality was reduced by 40% whenparenteral penicillin was administered before admission [20]. In
the United States and United Kingdom, penicillin resistance is
rare [17,21], and therefore, benzylpenicillin is the logical choice
for urgent prehospital treatment. However, when penicillins are
used, follow-up treatment with ceftriaxone, ciproﬂoxacin, or
rifampin is necessary to eliminate nasopharyngeal carriage
[17,19]. Chloramphenicol and meropenem can be used in cases of
Figure 2. Management of bacterial meningitis in children and young people. Incorporates NICE Bacterial Meningitis and Meningococcal Septicaemia Guideline CG102.
Distributed in partnership with NICE. ADH ¼ antidiuretic hormone; CSF ¼ cerebrospinal ﬂuid; CT ¼ computed tomography; HSV ¼ herpes simplex virus;
ICP ¼ intracranial pressure; IV ¼ intravenous; LP ¼ lumbar puncture; NICE ¼ National Institute of Health and Care Excellence; qds ¼ 4 times daily; TB ¼ tuberculosis;
WBC ¼ white blood cell.
S. Nadel / Journal of Adolescent Health 59 (2016) S21eS28S24penicillin allergy [17]. Empiric treatment with a third-generation
cephalosporin is recommended in developed countries until a
positive microbiological diagnosis is available, as there remains
the possibility of either penicillin resistance or alternative
diagnoses that might not be adequately treated by penicillin
therapy alone. Other more rare infectious causes of purpura
fulminans include Streptococcus pneumoniae, Staphylococcus
aureus, or other gram-negative bacteria. The recommended
duration of antibiotic therapy for IMD is a 5- to 7-day course of a
third-generation cephalosporin for both meningococcal menin-
gitis and septicemia [17].Biochemical and Hematologic Derangements
Meningococcal septicemia often results in derangements in
blood chemistry, including metabolic acidosis, hypoglycemia,
hypocalcemia, hypokalemia, hypomagnesemia, or hypo-
phosphatemia. Disseminated intravascular coagulation is
common; there may be bleeding from mucosal surfaces and
venipuncture sites. In addition, spontaneous pulmonary, gastric,
or cerebral hemorrhage may occur. The skin may be severely
compromised through inadequate perfusion as a result of
vasoconstriction and coagulopathy. Decreased skin perfusion
Figure 3. Algorithm for time-sensitive, goal-directed stepwise management of hemodynamic support in infants and children. CI ¼ cardiac index; CRRT ¼
continuous renal replacement therapy; CVP ¼ central venous pressure; ECMO ¼ extracorporeal membrane oxygenation; FATD ¼ femoral arterial thermodilution;
Hgb ¼ hemoglobin; IM ¼ intramuscular; IV ¼ intravenous; IO ¼ interosseous; MAP ¼ mean arterial pressure; PICCO ¼ pulse contour cardiac output; PICU ¼
pediatric intensive care unit; PIV ¼ peripheral intravenous; ScvO2 ¼ central venous oxygen saturation. Reproduced from Brierley J, Carcillo J, Choong K, et al.:
Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit
Care Med 2009; 37:666e688.
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Table 1
Antibiotics and dosages used to treat meningococcal meningitis [35,36]
Antibiotic Total daily dose
Children >1 month Adults
Penicillin G 4  106 units, q 4 hours 4  106 units, q 4 hours
Ceftriaxone 50 mg/kg, q 12 hours 2 g, q 12 hours
Cefotaxime 50 mg/kg, q 6 hours 2 g, q 4e6 hours
Ceftazidime 50 mg/kg, q 8 hours 2 g, q 8 hours
Cefepime 2 g, q 12 hours 2 g, q 8e12 hours
Ampicillin 75 mg/kg, q 6 hours 2e3 g, q 4 hours
Nafcillin and oxacillin 50 mg/kg, q 6 hours 2 g, q 4 hours
Vancomycin 15 mg/kg, q 6 hours 10e15 mg/kg, q 8 hours
Gentamicin and
tobramycin
2.5 mg/kg, q 8 hours 2 mg/kg, q 8 hours
Amikacin 10 mg/kg, q 8 hours 7.5 mg/kg, q 8 hours
Rifampin 6.7 mg/kg, q 8 hours 600 mg, q 24 hours
Meropenema,b 40 mg/kg, q 8 hours 2 g, q 8 hours
Chloramphenicolb 50 mg/kg, qid 4 hours 50 mg/kg, qid 4 hours
q ¼ every; qid ¼ every day.
a Use restricted to >3 months of age.
b Use in the case of penicillin allergy.
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edema from capillary leak may cause compartment syndrome.
Prophylaxis of Close Contacts
Of special note, all individuals in close contact with an
IMD-infected individual should receive chemoprophylaxis,
regardless of previous meningococcal immunization. A number
of antimicrobial agents are effective for chemoprophylaxis
against N. meningitidis (Table 2) [17].
Adjunctive Therapies
Steroids given before or with the ﬁrst dose of antibiotics
appear to reduce the incidence of neurologic sequelae in
Haemophilus inﬂuenzae type b meningitis and may be beneﬁcial
in pneumococcal meningitis [22]. There is also a reported trend
of improved outcomes with steroid therapy in meningococcal
meningitis [23]. Dexamethasone may be administered as
adjunctive therapy in children aged 6 weeks with meningo-
coccal meningitis, but the risk/beneﬁt ratio needs to beTable 2
Recommended chemoprophylaxis regimens for high-risk contacts and persons with i
Drug Dose Duration Efﬁcacy (
Rifampin
<1 month 5 mg/kg, orally, every 12 hours 2 days
1 month 10 mg/kg (maximum 600 mg),
orally, every 12 hours
2 days 90e95
Ceftriaxone
<15 years 125 mg, intramuscularly Single dose 90e95
15 years 250 mg, intramuscularly Single dose 90e95
Ciproﬂoxacin
1 month 20 mg/kg (maximum 500 mg),
orally
Single dose 90e95
Azithromycina 10 mg/kg (maximum 500 mg) Single dose 90
a Use only if ﬂuoroquinolone-resistant strains of N. meningitidis have not been iden
From American Academy of Pediatrics. Meningococcal Infections. In: Kimberlin D., Br
Academy of Pediatrics; 2015:547-558. Copyright  2015 American Academy of Pediaconsidered, and dosing should occur before or concomitant with
the ﬁrst dose of antibiotics [24].
High-dose dexamethasone should be given in cases of
suspected bacterial meningitis before (ideally within 4 hours), and
no longer than 12 hours following, the ﬁrst dose of parenteral
antibiotics; a dose of .15 mg/kg 4 times per day for 2e4 days is
recommended [14,25]. High-dose corticosteroid therapy is
contraindicated in meningococcal septicemia with shock in the
absenceofmeningitis becausehigh-dosecorticosteroidshavebeen
shown to worsen the outcomes of adults with septic shock [26].
There have only been two properly conducted, randomized
controlled studies of other adjunctive therapies in IMD and one
study examining a novel therapy for septic shock. In a random-
ized study of antiendotoxin antibody (HA-1A) conducted in
children with meningococcal septicemia, no signiﬁcant reduc-
tion in mortality was observed in children treated with HA-1A
compared with placebo [27]. Subsequent studies in adults with
gram-negative septicemia also showed no beneﬁt of therapy
with HA-1A [28]. In a randomized controlled trial of recombinant
bactericidal permeability-increasing protein (rBPI21), which
binds and neutralizes endotoxin and blocks the inﬂammatory
cascade, patients treatedwith rBPI21 suffered fewer amputations,
fewer blood product transfusions, and improved functional
outcomes compared with those treated with placebo [29]. The
study was not sufﬁciently powered to be able to detect a
reduction in mortality [29]. This product is no longer available.
A randomized controlled trial of activated protein C was
carried out in children with septic shock, with the primary end
point being reduction in time to resolve respiratory, cardiovas-
cular, and renal organ failure as surrogate indicators of mortality
[30]. The study was terminated early because it was felt it would
be unlikely to reach its primary end point, with suggestions of an
unfavorable risk/beneﬁt proﬁle.Post-Infection Sequelae
Amyriad of long-term complications are associated with IMD,
some of which are irreversible and disabling. Sequelae occur in
11%e19% of surviving IMD patients [17], and the most frequently
reported conditions are chronic pain, skin scarring, and neuro-
logic impairment. Other common complications include hearing
impairment, visual impairment, motor defects, behavioralnvasive meningococcal disease
%) Cautions
Can interfere with efﬁcacy of oral contraceptives and
some seizure prevention and anticoagulant medications;
may stain soft contact lenses.
Not recommended for pregnant women.
To decrease pain at injection site, dilute with 1% lidocaine.
To decrease pain at injection site, dilute with 1% lidocaine.
Not recommended routinely. Equivalent to rifampin for
eradication of Neisseria meningitidis from nasopharynx in one study
tiﬁed in the community.
ady M.T., Jackson M.A., et al., eds. Red Book 2015. Elk Grove Village, IL: American
trics. Reproduced with permission.
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include septic arthritis, conjunctivitis, and chronic meningo-
coccemia [17]. Hearing loss and amputations occur in approxi-
mately 3% of IMD cases [31].
Careful follow-up of patients with IMD should be routine.
Hearing tests are recommended within 4 weeks of hospital
discharge [14]. Orthopedic complications may be reported
several years after the acute infection due to bone growth plate
abnormalities and may need complex orthopedic procedures.
Multidisciplinary team involvement for amputation,
limb-ﬁtting, and rehabilitation are required in patents who suffer
amputation. More recently psychological and psychiatric
complications of IMD have become increasingly recognized in up
to one third of survivors. [32]. These include post-traumatic
stress disorder, anxiety, depression, and behavioral/educational
abnormalities. Management may require psychiatric and
psychological follow-up and intervention.
Post-infectious inﬂammatory syndrome occurs in approxi-
mately 6%e15% of individuals with IMD typically within
4e12 days of IMD onset [7]. Arthritis is the most common
inﬂammatory pathology associated with this syndrome and
results primarily from the accumulation of antigen-antibody
complexes that contain bacterial polysaccharide [7]. Approxi-
mately 10% of IMD cases have some form of arthritic sequelae
[33]. The most common type of post-infectious arthritis affects
one joint, particularly the knee, elbow, or ankle [34]. However,
multiple joint involvement can occur. Other sequelae character-
istics of post-infectious inﬂammatory syndrome include
vasculitis, pleuritis, pericarditis, iritis, and episcleritis [7]. Usu-
ally, treatment of these post-infectious complications requires
symptomatic treatment with antipyretics or nonsteroidal anti-
inﬂammatory agents. However, once ongoing infection has
been excluded, steroid treatment may be required, and the
prognosis of these complications is excellent.
Summary
IMD is a life-threatening infection with a rapid onset and
progression, so that early detection and prompt initiation of
parenteral antimicrobial therapy is paramount for optimizing
patient outcomes. Once the pathognomonic hemorrhagic rash
appears the diagnosis is immediately apparent, but establishing
the precise etiology of disease is important so that appropriate
public health procedures can be put into place as soon as possible.
LP is adeﬁnitivediagnostic tool that shouldbeused in caseswhere
the cause of meningitis is uncertain and where there is no
contraindication. Parenteral antibiotics should be administered
within 1 hour of IMD recognition to reduce the level of circulating
endotoxin, and thismaypreventor forestall complications suchas
septic shock and raised ICP. Physicians should be aware of
sequelae that can occur within days of IMD onset.
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